BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1500 related articles for article (PubMed ID: 17118313)

  • 41. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
    Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
    Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical impact of computed tomography-based image-guided brachytherapy for cervix cancer using the tandem-ring applicator - the Addenbrooke's experience.
    Tan LT; Coles CE; Hart C; Tait E
    Clin Oncol (R Coll Radiol); 2009 Apr; 21(3):175-82. PubMed ID: 19101130
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Preoperative concurrent radiation therapy and chemotherapy for operable bulky carcinomas of uterine cervix stages IB2, IIA, and IIB with proximal parametrial invasion].
    Lerouge D; Touboul E; Lefranc JP; Uzan S; Jannet D; Moureau-Zabotto L; Genestie C; Antoine M; Jamali M
    Cancer Radiother; 2004 Jun; 8(3):168-77. PubMed ID: 15217584
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative study of reference points by dosimetric analyses for late complications after uniform external radiotherapy and high-dose-rate brachytherapy for cervical cancer.
    Chen SW; Liang JA; Yeh LS; Yang SN; Shiau AC; Lin FJ
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):663-71. PubMed ID: 15380604
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High external parametrial dose can increase the probability of radiation proctitis in patients with uterine cervix cancer.
    Huang EY; Lin H; Hsu HC; Wang CJ; Chen HC; Sun LM; Hsiung CY
    Gynecol Oncol; 2000 Dec; 79(3):406-10. PubMed ID: 11104610
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dosimetric factors predicting severe radiation-induced bowel complications in patients with cervical cancer: combined effect of external parametrial dose and cumulative rectal dose.
    Huang EY; Wang CJ; Hsu HC; Hao Lin ; Chen HC; Sun LM
    Gynecol Oncol; 2004 Oct; 95(1):101-8. PubMed ID: 15385117
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term results of high-dose-rate brachytherapy in the primary treatment of medically inoperable stage I-II endometrial carcinoma.
    Niazi TM; Souhami L; Portelance L; Bahoric B; Gilbert L; Stanimir G
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1108-13. PubMed ID: 16099598
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Radiotherapy alone for invasive vaginal cancer: outcome with intracavitary high dose rate brachytherapy versus conventional low dose rate brachytherapy.
    Kucera H; Mock U; Knocke TH; Kucera E; Pötter R
    Acta Obstet Gynecol Scand; 2001 Apr; 80(4):355-60. PubMed ID: 11264612
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predictors of toxicity after image-guided high-dose-rate interstitial brachytherapy for gynecologic cancer.
    Lee LJ; Viswanathan AN
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1192-7. PubMed ID: 22592049
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A single institutional experience with definitive radiotherapy for cervical cancer using both high- and low-dose-rate brachytherapy.
    Gerszten K; Gooding WE; Lin Y; Heron DE; Faul C
    Gynecol Oncol; 2006 Sep; 102(3):500-7. PubMed ID: 16503346
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma.
    Lertsanguansinchai P; Lertbutsayanukul C; Shotelersuk K; Khorprasert C; Rojpornpradit P; Chottetanaprasith T; Srisuthep A; Suriyapee S; Jumpangern C; Tresukosol D; Charoonsantikul C
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1424-31. PubMed ID: 15275728
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical results of medium dose rate brachytherapy combined with external beam radiotherapy in the treatment of advanced cervical carcinoma.
    Ordeanu C; Coza O; Gavris S; Todor N; Szilagy E; Bako M; Cernea V; Ghilezan N; Nagy V
    J BUON; 2007; 12(2):221-6. PubMed ID: 17600876
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MRI-guided 3D optimization significantly improves DVH parameters of pulsed-dose-rate brachytherapy in locally advanced cervical cancer.
    Lindegaard JC; Tanderup K; Nielsen SK; Haack S; Gelineck J
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):756-64. PubMed ID: 18191335
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience.
    Kam MK; Teo PM; Chau RM; Cheung KY; Choi PH; Kwan WH; Leung SF; Zee B; Chan AT
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1440-50. PubMed ID: 15590175
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of pulsed-dose-rate brachytherapy in previously irradiated head-and-neck cancer.
    Strnad V; Geiger M; Lotter M; Sauer R
    Brachytherapy; 2003; 2(3):158-63. PubMed ID: 15062138
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biologically effective doses in medium dose rate brachytherapy of cancer of the cervix.
    Leborgne F; Fowler JF; Leborgne JH; Zubizarreta E; Chappell R
    Radiat Oncol Investig; 1997; 5(6):289-99. PubMed ID: 9436246
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of low and high dose rate brachytherapy in the treatment of uterine cervix cancer. Retrospective analysis of two sequential series.
    Ferrigno R; Nishimoto IN; Novaes PE; Pellizzon AC; Maia MA; Fogarolli RC; Salvajoli JV
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1108-16. PubMed ID: 15990016
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Does the entire uterus need to be treated in cancer of the cervix? Role of adaptive brachytherapy.
    Anker CJ; Cachoeira CV; Boucher KM; Rankin J; Gaffney DK
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):704-12. PubMed ID: 19473779
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multi-institutional phase II clinical study of concurrent chemoradiotherapy for locally advanced cervical cancer in East and Southeast Asia.
    Kato S; Ohno T; Thephamongkhol K; Chansilpa Y; Yuxing Y; Devi CR; Bustam AZ; Calaguas MJ; de los Reyes RH; Cho CK; Dung TA; Supriana N; Mizuno H; Nakano T; Tsujii H
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):751-7. PubMed ID: 19836154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 75.